Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 2/20 | 0.71 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.58 |
| ▸ | TSHR | P16473 | 4/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.58 |
| ▸ | STAT3 | P40763 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 5/20 | 0.56 |
| ▸ | NPC1 | O15118 | 4/20 | 0.56 |
| ▸ | RECQL | P46063 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17595755 | 0.83 | NOTUM (1.00) | NOTUMS1PR1SMN1; SMN2TSHRRAB9A | |
| SCHEMBL27657411 | 0.81 | S1PR1 (0.61) | S1PR1SMN1; SMN2TSHRLMNANR2F2 | |
| SCHEMBL4521919 | 0.81 | NOTUM (0.67) | NOTUMS1PR1SMN1; SMN2TSHRLMNA | |
| SCHEMBL4288756 | 0.81 | S1PR1 (0.61) | S1PR1SMN1; SMN2TSHRLMNANR2F2 | |
| SCHEMBL31049642 | 0.80 | NOTUM (0.70) | NOTUMSMN1; SMN2TSHRHTTRAB9A | |
| SCHEMBL5356293 | 0.80 | NOTUM (1.00) | NOTUMSMN1; SMN2TSHRHTTRAB9A | |
| SCHEMBL14948949 | 0.80 | NOTUM (0.70) | NOTUMS1PR1SMN1; SMN2LMNAHTT | |
| SCHEMBL6527881 | 0.80 | NOTUM (0.70) | NOTUMSMN1; SMN2TSHRLMNAHTT | |
| SCHEMBL6504714 | 0.80 | S1PR1 (0.65) | NOTUMS1PR1LMNAS1PR3MAPT | |
| SCHEMBL7149557 | 0.79 | SMN1; SMN2 (0.60) | S1PR1SMN1; SMN2TSHRLMNANR2F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8207147-B2 | Heterocyclic derivatives as GPCR receptor agonists | PROSIDION LIMITED (GB) | 2012-06-26 | — | — | US | disclosed |
| US-8207147-B2 | Heterocyclic derivatives as GPCR receptor agonists | PROSIDION LIMITED (GB) | 2012-06-26 | — | — | US | disclosed |
| US-8207147-B2 | Heterocyclic derivatives as GPCR receptor agonists | PROSIDION LIMITED (GB) | 2012-06-26 | — | — | US | disclosed |
| US-20090281060-A1 | HETEROCYCLIC DERIVATIVES AS GPCR RECEPTOR AGONISTS | PROSIDION LIMITED (GB) | 2009-11-12 | — | — | US | disclosed |
| US-20090281060-A1 | HETEROCYCLIC DERIVATIVES AS GPCR RECEPTOR AGONISTS | PROSIDION LIMITED (GB) | 2009-11-12 | — | — | US | disclosed |
| US-20090281060-A1 | HETEROCYCLIC DERIVATIVES AS GPCR RECEPTOR AGONISTS | PROSIDION LIMITED (GB) | 2009-11-12 | — | — | US | disclosed |
| EP-1711491-A1 | HETEROCYCLIC DERIVATIVES AS GPCR RECEPTOR AGONISTS | Prosidion Limited (GB) | 2006-10-18 | — | — | EP | disclosed |
| WO-2005061489-A1 | HETEROCYCLIC DERIVATIVES AS GPCR RECEPTOR AGONISTS | PROSIDION LIMITED (GB) | 2005-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281060-A1 | HETEROCYCLIC DERIVATIVES AS GPCR RECEPTOR AGONISTS | GPR119, GCGR, GLP1R | NOTUM 3957/4885S1PR1 490/4885SMN1; SMN2 2801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.